Pregnancy Clinical Trial
Official title:
Improving Multivitamin Supplementation to Pregnant Women
The purpose of this study is to compare the tolerability of Pregvit® to a common prenatal vitamin (Orifer® F) among pregnant women with morning sickness or those suffering from a variety of conditions.
Presently, there is a large choice of perinatal vitamins on the market. Materna® is taken by
70% of Canadian women. A recent study by the investigators team has shown that up to 35%-53%
of women with moderate to severe morning sickness discontinue their Materna®. One main
reason is that its large size causes difficulties in swallowing, which prompts women to stop
taking the drug. The second main reason for stopping is gastrointestinal adverse effects
from the iron content, which causes nausea, vomiting and constipation.
A new periconceptional multivitamin supplement, Pregvit®, was introduced to the market in
September 2003 by the Canadian company Duchesnay Inc. with the aim of trying to overcome the
disadvantages of the existing multivitamin supplements. PregVit® is a prenatal multivitamin
that contains 35 mg elemental iron, as ferrous fumarate. It is formulated into 2 small
tablets (each tablet:16 mm × 9 mm × 4 mm), containing different vitamins and minerals,
particularly separating the iron (morning tablet) from the calcium (evening tablet) to
optimize iron absorption. The use of PregVit® requires a physician's prescription.
Since Materna® or other generic products are the most commonly used non-prescription (i.e.
over-the-counter) prenatal multivitamins, they were not selected for comparison in the study
because enrolled subjects who had discontinued a prenatal multivitamin most likely had
discontinued any one of them. Ethically, subjects in this situation cannot be randomized to
resume Materna® or another generic prenatal multivitamin.
Instead, Orifer F® was selected as the small-tablet prenatal multivitamin (one tablet: 5 mm
radius, 5 mm thickness), containing a high iron content (60 mg elemental iron as ferrous
sulphate). It is taken daily as a single tablet and the use of Orifer F® does not require a
physician prescription (i.e. over-the-counter).
Comparing tolerability of PregVit® to Orifer F® would address separation of the potential
effect of iron content from that of tablet size on multivitamin tolerability among pregnant
women and women suffering from morning sickness or those suffering from a variety of
conditions such as, Crohn's Disease, Ulcerative Colitis, Peptic-Duodenal Ulcer, Irritable
Bowel Syndrome, Celiac Disease, as well as anemia or hypothyroidism.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03442582 -
Afluria Pregnancy Registry
|
||
Terminated |
NCT02161861 -
Improvement of IVF Fertilization Rates, by the Cyclic Tripeptide FEE - Prospective Randomized Study
|
N/A | |
Not yet recruiting |
NCT05934318 -
L-ArGinine to pRevent advErse prEgnancy Outcomes (AGREE)
|
N/A | |
Enrolling by invitation |
NCT05415371 -
Persistent Poverty Counties Pregnant Women With Medicaid
|
N/A | |
Completed |
NCT04548102 -
Effects of Fetal Movement Counting on Maternal and Fetal Outcome Among High Risk Pregnant Woman
|
N/A | |
Completed |
NCT03218956 -
Protein Requirement During Lactation
|
N/A | |
Completed |
NCT02191605 -
Computer-delivered Screening & Brief Intervention for Marijuana Use in Pregnancy
|
N/A | |
Completed |
NCT02223637 -
Meningococcal Quadrivalent CRM-197 Conjugate Vaccine Pregnancy Registry
|
||
Recruiting |
NCT06049953 -
Maternal And Infant Antipsychotic Study
|
||
Completed |
NCT02577536 -
PregSource: Crowdsourcing to Understand Pregnancy
|
||
Not yet recruiting |
NCT06336434 -
CREATE - Cabotegravir & Rilpivirine Antiretroviral Therapy in Pregnancy
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT05412238 -
Formulation and Evaluation of the Efficacy of Macro- and Micronutrient Sachets on Pregnant Mothers and Children Aged 6-60 Months
|
N/A | |
Not yet recruiting |
NCT04786587 -
Alcohol Self-reporting During Pregnancy. AUTOQUEST Study.
|
||
Not yet recruiting |
NCT05028387 -
Telemedicine Medical Abortion Service Using the "No-test" Protocol in Ukraine and Uzbekistan.
|
||
Completed |
NCT02783170 -
Safety and Immunogenicity of Simultaneous Tdap and IIV in Pregnant Women
|
Phase 4 | |
Completed |
NCT02683005 -
Study of Hepatitis C Treatment During Pregnancy
|
Phase 1 | |
Recruiting |
NCT02619188 -
Nutritional Markers in Normal and Hyperemesis Pregnancies
|
N/A | |
Recruiting |
NCT02507180 -
Safely Ruling Out Deep Vein Thrombosis in Pregnancy With the LEFt Clinical Decision Rule and D-Dimer
|
||
Recruiting |
NCT02564250 -
Maternal Metabolism and Pregnancy Outcomes in Obese Pregnant Women
|
N/A | |
Completed |
NCT02523755 -
Evaluation of Regional Distribution of Ventilation During Labor With or Without Epidural Analgesia
|
Phase 4 |